9 Participants Needed

Genetically Modified T-Cells for Pancreatic Cancer

II
Overseen ByIMTX Intake Coordinator
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial tests a new treatment for advanced pancreatic cancer using modified immune cells from the patient. These cells are changed to better recognize and attack cancer cells. The goal is to find the best dose and see if this approach can help patients whose cancer has spread.

Research Team

EG

Elena Chiorean

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Eligibility Criteria

Adults with metastatic pancreatic ductal adenocarcinoma who've had at least one systemic therapy can join. They must have a life expectancy over 3 months, be willing to undergo tumor biopsies, and not have received recent treatments that could interfere. Participants need properly functioning major organs, no severe autoimmune diseases or organ transplants, and agree to use contraception.

Inclusion Criteria

I have had at least one treatment for cancer that has spread.
Estimated glomerular filtration rate (eGFR) > 60 mL/min
Total bilirubin (bili) =< 1.5 X ULN. Patients with suspected Gilbert syndrome may be included if total bili > 3 mg/dL but no other evidence of hepatic dysfunction
See 25 more

Exclusion Criteria

Concurrent use of other investigational anti-cancer agents
Active autoimmune disease
I currently have an infection that isn't under control.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Lymphodepletion Chemotherapy

Patients receive cyclophosphamide and fludarabine intravenously on days -5, -4, and -3 or optionally bendamustine on days -4 and -3 prior to the first T cell infusion

1 week
3 visits (in-person)

T-Cell Therapy

Patients receive FH-TCR-Tᴍsʟɴ intravenously over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity

6 weeks
3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 1 year

Treatment Details

Interventions

  • Autologous Mesothelin-specific TCR-T Cells
Trial Overview The trial is testing FH-TCR-Tᴍsʟɴ T-cells designed to target mesothelin on cancer cells combined with chemotherapy drugs like cyclophosphamide and fludarabine. The goal is to find the safest dose that helps these modified T-cells better attack the tumor cells in patients with advanced pancreatic cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Cohorts I, II, and III (FH-TCR Tᴍsʟɴ)Experimental Treatment4 Interventions
LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -5, -4 and -3 or may optionally receive bendamustine IV on days -4 and -3 prior to the 1st T cell infusion. T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity.
Group II: Cohort IV (FH-TCR Tᴍsʟɴ) (Discontinued with amendment 3/28/23)Experimental Treatment3 Interventions
LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -3 to -1. T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Fred Hutchinson Cancer Center

Lead Sponsor

Trials
583
Recruited
1,341,000+

Fred Hutchinson Cancer Research Center

Lead Sponsor

Trials
444
Recruited
148,000+

Lonza Walkersville, Inc.

Industry Sponsor

Trials
1
Recruited
9+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security